Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAAP: EMP16-02 for Weight Loss in Obesity
NCT04521751Phase 2Completed
- Sponsor
- Empros Pharma
- Start
- May 2020
- Primary completion
- Aug 2021
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of EMP16 in obesity, Overweight, sponsored by Empros Pharma. Started May 2020; status: completed.
02
Drugs
EMP16
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04521751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521751.